Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
5.1
-46.88%
40%
—
26.52%
80%
—
5 Years
Score5.1
Net Growth-46.88%
Net Trend40%
Net Income Consistency—
Rev Growth26.52%
Rev Trend80%
Revenue Consistency—
Novartis AG ADR fundamental performance
Between 2020 and 2025, revenue grew from $ 49.89B to $ 54.81B and net income grew from $ 8.07B to $ 14.05B. Revenue increased in 4 of those 5 years; net income in 2.
Across Novartis AG ADR's full reported history, from 1998 to 2025, revenue grew from $ 23.03B to $ 54.81B and net income grew from $ 4.36B to $ 14.05B. Revenue increased in 71% of the years measured; net income in 61%.
Novartis AG ADR currently holds a 20-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 152.32 | — |
1 Year2025-08-12 | $ 115.79 | 31.55% |
5 Years2021-08-12 | $ 77.02 | 97.78% |
10 Years2016-08-12 | $ 51.02 | 198.55% |
20 Years2006-08-11 | $ 24.24 | 6x |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 |
|---|---|---|---|---|---|
| Price | $ 152.32 | $ 115.79 | $ 77.02 | $ 51.02 | $ 24.24 |
| Return | — | 31.55% | 97.78% | 198.55% | 6x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 55.63B | $ 12.75B | $ 7.69B |
| 2025 | $ 54.81B | $ 14.05B | $ 11.59B |
| 2024 | $ 51.72B | $ 11.94B | $ 13.35B |
| 2023 | $ 46.66B | $ 14.85B | $ 13.96B |
| 2022 | $ 43.46B | $ 6.95B | $ 18.61B |
| 2021 | $ 43.97B | $ 24.02B | $ 28.11B |
| 2020 | $ 49.89B | $ 8.07B | $ 11.56B |
| 2019 | $ 48.67B | $ 11.73B | $ 11.44B |
| 2018 | $ 46.09B | $ 12.61B | $ 15.96B |
| 2017 | $ 43.40B | $ 7.70B | $ 9.48B |
| 2016 | $ 49.43B | $ 6.71B | $ 7.77B |
| 2015 | $ 50.38B | $ 17.78B | $ 5.44B |
| 2014 | $ 53.63B | $ 10.21B | $ 13.86B |
| 2013 | $ 52.71B | $ 9.17B | $ 9.22B |
| 2012 | $ 51.97B | $ 9.27B | $ 8.11B |
| 2011 | $ 59.37B | $ 8.94B | $ 5.07B |
| 2010 | $ 51.56B | $ 9.79B | $ 8.13B |
| 2009 | $ 45.10B | $ 8.40B | $ 17.44B |
| 2008 | $ 42.58B | $ 8.19B | $ 6.11B |
| 2007 | $ 38.94B | $ 11.94B | $ 13.20B |
| 2006 | $ 35.10B | $ 7.17B | $ 7.95B |
| 2005 | $ 29.75B | $ 6.13B | $ 10.93B |
| 2004 | $ 27.27B | $ 5.36B | $ 14.59B |
| 2003 | $ 24.93B | $ 4.74B | $ 13.25B |
| 2002 | $ 20.87B | $ 4.72B | $ 12.57B |
| 2001 | $ 18.76B | $ 3.83B | $ 13.18B |
| 2000 | $ 22.18B | $ 4.46B | $ 12.51B |
| 1999 | $ 20.38B | $ 4.18B | $ 10.26B |
| 1998 | $ 23.03B | $ 4.36B | $ 9.69B |
Explore beyond NVS
You're looking at Novartis AG ADR. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
